Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

38 results about "OralSuspension" patented technology

Lipophilic Drug Suspensions

An oral suspension pharmaceutical composition is disclosed for water soluble salts of arylalkanoic acid (NSAID) drugs such as ibuprofen and naproxen. When mixed with glyceryl esters such as glyceryl caprate / caprylate and water, the resulting combination forms a “liquid scaffold” structure that reliably enables the suspension of significant quantities of said arylalkanoic acid drugs. For example, suspensions containing 25% w / w arylalkanoic acid may be obtained using the aforementioned combination. Suspensions comprising further pharmaceutically active agents, in addition to said arylalkanoic acids, may also be prepared. Also disclosed is a binary blend of glyceryl caprate / caprylate and the sodium salt of ibuprofen and a ternary blend of glyceryl caprate / caprylate and the potassium salt of ibuprofen.
Owner:IBUMIX LTD

Pharmaceutical composition comprising ibuprofen

The present invention refers to pharmaceutical compositions comprising ibuprofen or a pharmaceutically acceptable derivative thereof and one or more solubilizing agents in the form of A) aqueous solution for use in intravenous administration comprising ibuprofen of either the sodium or lysinate salt, paracetamol and preferably one or more cyclodextrins or B) aqueous solution for use in intravenous administration wherein the one or more solubilizing agents are one or more essential amino acids and optionally one or more cyclodextrins or C) composition for use in oral administration, which comprises paracetamol and cyclodextrin, wherein said composition is in the form of either i) effervescent tablets or effervescent granules or ii) oral suspension or syrup or oral solution or iii) soft capsules.
Owner:TSETI IOULIA

A vinblastine suspension and a preparation method thereof

This invention belongs to the field of pharmaceutical formulation technology and provides a vinpocetine suspension and its preparation method. The vinpocetine suspension of this invention comprises the following raw materials in specific mass parts: vinpocetine, a suspending agent, a solubilizer, a stabilizer, and water. The vinpocetine suspension of this invention is suitable for oral administration. The excipients in the suspension include a suspending agent, a solubilizer, and a stabilizer. The solubilizer inhibits the aggregation of vinpocetine nanoparticles and improves the solubility and dispersion uniformity of vinpocetine nanoparticles in water. The suspending agent and stabilizer together construct a spatially stable structure, ensuring the suspension and dispersion of vinpocetine nanoparticles and resisting sedimentation. The suspending agent, solubilizer, and stabilizer work synergistically to achieve nanoscale distribution and uniform dispersion and suspension of vinpocetine, significantly improving the bioavailability of vinpocetine. High-pressure homogenization achieves nanoscale distribution of vinpocetine, with a particle size of 200-300 nm.
Owner:SOUTHEAST UNIV CHENGXIAN COLLEGE

Room stable hydroxyurea oral suspension

The present invention provides a liquid composition comprising effective amount of Hydroxyurea for oral administration. The invention further discloses liquid formulation in form of ready to use oral suspension which remains stable at room temperature at the time of dispensing, storage and even after reopening of the container comprising the suspension. Also provided is a method of preparing the formulation and treating sickle cell anemia in pediatric patients.
Owner:AKUMS DRUGS & PHARMA

New prescription

An oral formulation of granules of an active ingredient such as gepotidacin or a pharmaceutically acceptable salt thereof that rapidly disperses in water, or an oral formulation comprising such granules. Such granules provide an oral suspension with good mouthfeel and palatability. This oral suspension is particularly useful for pediatric patient populations or patient populations with difficulty swallowing.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

An oral suspension of sodium zirconium cyclosilicate and its preparation method

The present invention discloses a sodium zirconium cyclosilicate oral suspension and a preparation method thereof, which comprise the following components in mass percentages: 10-30% of sodium zirconium cyclosilicate, 0.1-2.0% of cellulose, 0.01-0.30% of suspending agent, 0-10% of flavoring agent, 0-1.0% of preservative, and purified water; the suspending agent is a mixture of xanthan gum and locust bean gum. The potassium ion exchange capacity of the sodium zirconium cyclosilicate oral suspension of the present invention is equivalent to that of the commercially available powder and has good dispersion stability.
Owner:SSH (HANGZHOU) PHARMACEUTICAL CO LTD

Anhydroicaritin nanocrystal oral suspension and preparation method thereof

The invention belongs to the technical field of pharmaceutical preparations, and relates to an anhydroicaritin nanocrystal oral suspension and a preparation method thereof. The oral suspension contains anhydroicaritin nanocrystals, a suspending aid, a surfactant, a buffer salt system and other pharmaceutically acceptable auxiliary materials. By optimizing the surfactant system and the pH range, the stability of the anhydroicaritin is effectively improved. The problem of long-term stability of a nanocrystalline oral suspension preparation prepared from anhydroicaritin is solved. According to the prescription, the dissolution speed of the medicine is increased, the bioavailability is improved, and the preparation method is easy to operate, stable in process and suitable for industrial production.
Owner:LUNAN BETTER PHARMA

Azilsartan and amlodipine besylate oral suspension and preparation method thereof

The invention relates to an azilsartan and amlodipine besylate oral suspension and a preparation method thereof. The azilsartan and amlodipine besylate oral suspension takes azilsartan and amlodipine besylate as active ingredients, xanthan gum and croscarmellose sodium as suspending aids, and water and glycerol as solvents; the mass ratio of xanthan gum to croscarmellose sodium is (20-30): (5-8). The compound of the croscarmellose sodium and the xanthan gum is used as a suspending aid, so that the azilsartan and the amlodipine besylate in the oral suspension can be ensured to be dispersed in colloid, cannot settle and gather, and are high in stability. When the suspension is taken, the suspension is convenient for adult patients with swallowing difficulty to use, the accuracy of administration dosage is ensured, the safety and effectiveness of the medicine are improved, and the problems of high viscosity and caking caused by long-time placement of a common suspension are solved.
Owner:XINJIYUAN (BEIJING) PHARM TECH CO LTD

A powder composition for oral suspension of proton pump inhibitors and the method of preparing the same

Powder composition for oral suspension comprising a two phase powder mixture, where the first phase is in powder form comprising a Proton Pump Inhibitor (e.g. omeprazole) or pharmaceutically acceptable salts thereof in an amount of 0.01-7.5 % by weight, at least one diluent (e.g. mannitol), a first buffering agent (e.g. sodium hydrogen carbonate), a binding agent (e.g. xanthan gum), and the second phase is in powder form comprising a second buffering agent, a viscosity enhancer (e.g. sodium alginate) in the range 0.0010 %w / w to 2.0 wt.%, at least one diluent; at least one preservative (e.g. sodium benzoate, sodium methyl para hydroxy benzoate), a diluent, and an excipient (e.g. a flavour). Preferably, the second buffering agent is a carbonate or hydrogen carbonate. Preferably, the D50 of the omeprazole, if present, is 1.5-5.5 microns. The composition may be used in the treatment of erosive oesophagitis, gastroesophageal reflux, gastric ulcers etc.
Owner:ORBIT PHARMA LTD

Edaravone oral preparation and improved preparation method thereof

The present invention relates to a powder for an edaravone oral suspension dosage form. The invention also relates to providing patient compliant, economical and technically advanced dosage forms over existing dosage forms. In addition, compared with the prior art, the patient compliance edaravone preparation prepared according to the invention is proved to be higher in solubility and stability. In addition, the present invention also provides a powder composition for oral suspension prepared by an improved method that is relatively simple, easy for commercial production, and replicable in function.
Owner:BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED

An oral suspension of an antitubercular drug and a method for preparing the same

PendingCN122320872AOral suspensionsActive agent
This invention discloses an oral suspension of an anti-tuberculosis drug and its preparation method. The oral suspension contains an anti-tuberculosis drug, a suspending agent, a surfactant, an antibacterial agent, an antioxidant, a flavoring agent, and a pH adjuster. It has technical advantages such as stable physical and chemical properties, uniform content, and easy long-term storage.
Owner:JIANGSU RUNHENG PHARMACEUTICAL CO LTD

Stable oral suspensions of baclofen

The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg / mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.
Owner:ANI PHARMA

Stable eplerenone oral suspension and preparation method thereof

The invention discloses a stable eplerenone oral suspension and a preparation method thereof. According to the oral suspension, a buffer pair pH regulator is adopted to regulate the pH value of the oral suspension of the system to 3.0-5.0, so that the stability of the product in the storage process is maintained. Meanwhile, compared with eplerenone tablets, the eplerenone oral suspension provided by the invention has the advantages that the absorption is faster, the in-vivo exposure of the medicine is larger, the bioavailability is obviously improved by about 50%, and a reliable high-stability and high-bioavailability eplerenone oral suspension preparation scheme is provided clinically.
Owner:NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD +1

Anhydroicaritin nanocrystal oral suspension as well as preparation method and application thereof

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to anhydroicaritin nanocrystalline oral suspension and a preparation method thereof. The oral suspension disclosed by the invention contains anhydroicaritin nanocrystals, a space protecting agent, a surfactant, a preservative, a pH regulator and other pharmaceutically acceptable auxiliary materials. Compared with the prior art, the problem that the stability is poor after the anhydroicaritin is prepared into the nanocrystal is solved; particle size distribution is uniform, and aggregation and layering phenomena are avoided; related substances are controllable, the safety is higher, the taste is good, the dosage can be accurately divided according to the body weight, and children, old people and patients with dysphagia can take the medicine conveniently. The oral suspension is simple in preparation method and suitable for industrial production.
Owner:LUNAN BETTER PHARMA

Fexofenadine Hydrochloride Oral Suspension and Its Preparation Method

This application relates to the field of medicine, and specifically discloses a fexofenadine hydrochloride oral suspension and a preparation method thereof. The oral suspension includes an active ingredient and excipients. The active ingredient is fexofenadine hydrochloride, and the excipients at least include a flavoring agent, a suspending agent, a preservative, and a dispersing aid. The suspending agent includes one or both of sodium carboxymethylcellulose and hydroxypropyl methylcellulose; the dispersing aid is a mixture of polyvinylpyrrolidone and gelatinized modified microcrystalline cellulose; the preparation method includes the following steps: S1. Add water, then add a buffer solution, stir to dissolve, add the dispersing aid, and then add fexofenadine hydrochloride, and stir to obtain raw material A; S2. Mix water and the preservative to obtain raw material B; S3. Add the suspending agent to raw material A, then add raw material B, mix and stir, add the flavoring agent, and add the remaining water to make up the volume to obtain the product. This application has the advantage that the prepared fexofenadine hydrochloride oral suspension has good redispersibility.
Owner:HANGZHOU HONGYOU PHARM TECH CO LTD

Formulation and manufacturing process of liquid formulation of rilpivirine

The present invention provides a manufacturing method of rilpivirine oral suspension with a specific loading of rilpivirine of 30-35 mg / mL. The oral suspension produced have a controlled pH and thixotropy, which are essential to facilitate the dissolution of rilpivirine hydrochloride into and even distribution and stability maintenance of the rilpivirine in the suspension, optimizing shelf life and efficacy of the suspension while also enabling convenient and palatable administration.
Owner:APTORUM THERAPEUTICS LIMITED

Vonoprazan fumarate suspension and preparation method thereof

The invention discloses a fumaric acid Vonoprazan suspension and a preparation method thereof, the fumaric acid Vonoprazan suspension is prepared from fumaric acid Vonoprazan, a suspending aid, a wetting agent, an acidifying agent, a flavoring agent and essence, the prepared preparation is easier to swallow compared with tablets, proper auxiliary materials are screened and added through a prescription, the bitter taste of the fumaric acid Vonoprazan during oral administration is obviously reduced, and the oral administration effect of the fumaric acid Vonoprazan is improved. The clinical compliance of a patient is improved; and the defects that the tablet is taken after being broken apart, the dosage is not accurate enough, the coating is damaged and the taste masking effect is influenced are overcome. The oral suspension is packaged in unit dose, and is accurate in dose and convenient to administrate.
Owner:GUIZHOU FANDE PHARM CO LTD

A powder composition for oral suspension of proton pump inhibitors and the method of preparing the same

The present invention relates to a powder composition for oral suspension of Proton Pump Inhibitor or pharmaceutically acceptable salts thereof for oral administration. The powder composition for oral suspension comprises a two phase powder mixture, where the first phase is in powder form comprising a Proton Pump Inhibitor or pharmaceutically acceptable salts thereof, at least one diluent, a first buffering agent, a binding agent, and the second phase is in powder form comprising a second buffering agent, a viscosity enhancer, at least one diluent; at least one preservative, a sweetener, and a flavour. The powder composition for oral suspension of Proton Pump Inhibitors provides the convenience of administration for the paediatric and geriatric patients, provide improved palatability of bitter drugs, and improve the solubility of Proton Pump Inhibitors of BCS class-II of biopharmaceutical classification system.
Owner:ORBIT PHARMA LTD

Atorvastatin calcium oral suspension as well as preparation method and application thereof

The invention discloses a preparation method of an atorvastatin calcium oral suspension, and belongs to the technical field of pharmaceutical preparations. The preparation method provided by the invention comprises the following steps: adding part of water into a liquid preparation container, heating and carrying out nitrogen filling treatment, then adding a preservative and part of a suspending aid, and stirring to obtain first liquid; the suspending aid comprises Arabic gum; adding a part of water into another container, carrying out nitrogen charging treatment, then adding the remaining suspending aid and atorvastatin calcium, carrying out shearing dispersion, then mixing with the second liquid, then adding a flavoring agent and the remaining water, carrying out volume metering and nitrogen charging, and controlling the dissolved oxygen content to be less than 3mg / L; and filling into a bottle purged by nitrogen, carrying out headspace nitrogen charging after the filling is finished, so that the residual oxygen content in the bottle is below 5%, and sealing a cover. According to the invention, the physical stability and chemical stability of the atorvastatin calcium oral suspension are remarkably improved, and meanwhile, compared with the existing dosage form, the dosage form of the obtained oral suspension has better patient compliance and flexibility.
Owner:YUANFANG NEW DRUG (BEIJING) TECHNOLOGY CO LTD

A perampanel oral suspension and its preparation method

This invention discloses a perampanel oral suspension and its preparation method. The preparation method of this invention includes the following steps: S1, adding microcrystalline cellulose sodium carboxymethyl cellulose co-treatment material to water for homogenization to obtain a first dispersion; S2, adding sorbitol, an antibacterial agent, and a pH adjuster to the first dispersion to obtain a second dispersion; S3, pulverizing perampanel and sieving it to control the particle size D. 90 The sample size is 10–15 μm; S4, the perampanel obtained in step S3 is subjected to antistatic treatment; S5, the perampanel treated in step S4, defoamer, and polyoxyethylene hydrogenated castor oil are added to the second dispersion to obtain the third dispersion; S6, water is added to the third dispersion to bring it to a final volume, and homogenization is performed to obtain the perampanel oral suspension. This method can significantly improve the dissolution rate, long-term stability, and control level of drug-related substances at day 0, and improve the uniformity of content.
Owner:JINZHOU AHON PHARM CO LTD

Detection method of brexpiprazole oral suspension

The invention belongs to the technical field of pharmaceutical analysis, and provides a detection method of a brexpiprazole oral suspension, which adopts reverse high performance liquid chromatography for detection, can realize effective separation of brexpiprazole and impurities thereof, can also realize effective separation of brexpiprazole and impurities thereof and preservatives, is simple and convenient to operate, has good specificity and high sensitivity, and can be applied to detection of oral suspension of brexpiprazole. The control requirement of the limit of 0.5% is met, and the method can be used for quality control of the brexpiprazole oral suspension.
Owner:SHANDONG BESTCOMM PHARMA CO LTD

Pharmaceutical composition of amisulpride, suspension and preparation method thereof

The invention belongs to the field of pharmaceutical preparations, and particularly relates to an amisulpride pharmaceutical composition, an oral suspension prepared from the amisulpride pharmaceutical composition and a corresponding preparation method. The composition disclosed by the invention is mainly composed of amisulpride and polyvinyl alcohol, other pharmaceutical auxiliary materials can be added to prepare an oral suspension, polyvinyl alcohol has the dual effects of modifying taste and assisting suspension, the composition has excellent stability, the bitter taste of amisulpride in a preparation is remarkably improved, and the medication compliance of a patient is improved.
Owner:PHARMA CHANGZHOU PHARMA FACTORY NO 4 +1

Oral suspensions comprising temozolomide or lenalidomide

The present disclosure provides a composition comprising temozolomide or lenalidomide, a medium chain triglyceride such as miglyol, silicon dioxide and a surfactant, wherein the composition optionally comprises an antioxidant and / or a flavoring agent, and wherein the temozolomide composition is a non-aqueous, preservative free suspension. Also provided is a method for treating cancer in a subject, such as a child or a subject suffering dysphagia and / or has difficulty swallowing.
Owner:SHORLA PHARMA LTD

Palatable icosapent ethyl formulation with statin and method thereof

The disclosed embodiment relates to a palatable icosapent ethyl formulation with statin. More particularly, the formulation comprises of icosapent ethyl, antioxidant, statin, alkalizer, wetting agent, suspending agent, diluent, flavouring agent, and sweetening agent. Furthermore, the statin is rosuvastatin calcium; the antioxidant is tocopherol; the alkalizer is magnesium oxide; the wetting agent is docusate sodium; the suspending agent is colloidal silicon dioxide; the diluent is miglyol 812; the flavouring agent is peppermint oil; and the sweetening agent is sucralose. The said formulation is an oral suspension for reduction of triglyceride (TG) levels and stabilization of atherosclerotic plaque.
Owner:ALTHERA LABORATORIES INDIA PVT LTD

Ion exchange resin-based paliperidone long-acting oral suspension and preparation method thereof

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a paliperidone long-acting oral suspension based on ion exchange resin and a preparation method of the paliperidone long-acting oral suspension. The cation exchange resin and the paliperidone are adopted to form a medicine-resin compound, pH responsive release is achieved through ionic bonds, and the effects of low dissociation in gastric juice and slow release in intestinal juice are achieved; meanwhile, a ready-to-use oral suspension is developed for patients with dysphagia, a flavoring agent is added, the taste is improved, compared with controlled release tablets, the compliance of the patients can be improved, the medication convenience can be improved, and the paliperidone long-acting oral suspension preparation has a good application prospect.
Owner:南京康川济医药科技有限公司